Home2020-01-23T19:50:26+00:00
Loading...
Loading...

Spotlight

Twitter feed

Current and future progress to overcoming targeted drug resistance for #GastrointestinalCancers https://t.co/X8OXhLOpgp #ASCOEdBook #GICSM #GI21

Dr. Laurie Glimcher (@LGlimcherMD) spoke with @GreaterBoston's @jimbraude about the importance of cancer patients receiving the #COVID19 vaccine. Patients, survivors & family, remember to tune in today at 5 pm EST for a virtual discussion on the #vaccine

gb_20210126_seg_c_pic.jpg

Dana-Farber CEO Highlights Importance Of Vaccinating Cancer Patients Against COVID-19

Doctor Laurie Glimcher, CEO of the Dana-Farber Cancer Institute, joined Jim Braude to discuss the importance ensuring vaccinations for a particularly ...

ms.spr.ly

Sonia Rocha @srochaliv @LivUni, @MKoritzinsky @PMResearch_UHN, and Paul Boutros @TheBoutrosLab @UCLA will discuss Hypoxia in a plenary session at the AACR virtual conference on Radiation Science and Medicine, March 2-3.
Learn more:
https://t.co/aqlKyDqWfR
#AACRrsm21

Continuity of Cancer Care in #COVID19:
@peters_solange, @TMWiseDraper, @SheenaBhallaMD, @ZhuoerXie, Karely Mann @huntsmancancer, and Giuseppe Curigliano @curijoey will address this topic at the #AACRCovid and Cancer virtual conference, Feb 3-5:
https://t.co/Ok54m7Ch8e

OPERA trial: Most patients with cT2, cT3a, or cT3b rectal cancer who develop a CR to treatment can forego surgery after neoadjuvant CRT plus an additional radiotherapy boost w/out compromising chance of cure #GI21 #ASCODailyNews

Organ Preservation Possible for Most Patients With Early or Locally Advanced Rectal Cancer

An early look at the data from the phase III OPERA (Organ Preservation in Early Rectal Adenocarcinoma) trial suggests that most patients with cT2, cT3...

fal.cn

“Due to the pandemic, there is a much greater appreciation of the immune system among the general public.”
Marcela Maus, MD, PhD @harvardmed discussed some of the challenges and opportunities in immunotherapy in 2021. #AACRBlog
https://t.co/yuTE81XTsv

AACR Affiliate-Advocate membership is open to survivors and advocates from organizations whose mission includes the advancement of cancer research. Member benefits include free registration to #AACR21 and 2021 Special Conferences. Learn more:
https://t.co/xz1r6JQlsh

Neoadjuvant #chemotherapy alters the immune microenvironment within PDAC, & different #chemo regimens exert different effects. This data may help determine how best to utilize chemotherapy in PDAC to maximize efficacy #GI21 #ASCODailyNews

Analysis of the PDAC Immune Microenvironment Sheds Light on the Effects of Chemotherapy, Informing Future Treatment Strategies

An exploratory study reveals that neoadjuvant chemotherapy alters the immune microenvironment within pancreatic ductal adenocarcinoma (PDAC), and diff...

fal.cn

Dana-Farber to host a virtual discussion for cancer patients and survivors about the #COVID19 vaccine: https://t.co/JANtibhgOH

Join us on Wednesday, January 27th at 5:00 pm EST ⬇💉

Recent publications

Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma. Clin Cancer Res.

Dynamic single-cell RNA sequencing identifies immunotherapy persister cells following PD-1 blockade. J Clin Invest.

All publications

Announcements

We’re pleased to share a new section on our site, “Our stories,” which will profile staff from the Belfer team. Our first story is Sarah Musoke (Nzikoba). Read Sarah’s story.

Research

Target identification and validation image
Target identification and validation
Photo of scientist carefully adding fluid to multiple test tubes
Drug discovery and development
Photo of Belfer Center researcher working at computer
Clinical science and correlatives

Strategic alliances

Graphic showing circular relationship of research, medicine, and industry

Our strategic alliances drive research innovations and lead to improved therapies to benefit cancer patients

Collaborate with us

Our people

Background image is a collage of photos showing Belfer Center members
Our team
Our culture
Background image is a collage of photos showing Belfer Center members

Donor highlight

Robert and Renée Belfer’s transformative cumulative Dana-Farber investment of more than $25 million launched the Robert A. and Renée E. Belfer Center for Applied Cancer Science. Their generosity enabled the Belfer Center to integrate its scientific teams, produce innovative cancer models, partner with industry leaders, and accelerate the development of revolutionary therapies to treat cancer. We are grateful for their vision and incredible support.

Photo of donors, Mr. and Mrs Belfer
Go to Top